RVO
HomeMarketplace

ServiceUpdated on 10 September 2025

Biopanning on Live Cells

Peter Timmerman

Head of Peptide Science at Biosynth B.V.

Lelystad, Netherlands

About

High-diversity screening using phage-display libraries is usually performed with recombinant proteins. However, for membrane-integrated proteins, like GPCR's and ion-channels, this is no option since these proteins do not adopt the correct conformation when recombinantly expressed. Biosynth offers a brandnew platform for biopanning on live cells, which uses the target proteins in their natural form, i.e. embedded in the cell-surface membrane of these cells. Our first successful screening-campaigns convincingly show that this platform provides solid binders to intact cell-surface proteins that cannot be obtained using the conventional modes of biopanning, i.e. using recombinant proteins.

Type

  • Development
  • Manufacturing

Applies to

  • Innovative therapies - Precision medicine
  • Development stages and support fuctions - Pre-clinical research and development
  • Development stages and support fuctions - Contract research (CRO / CRMO)

Organisation

Biosynth B.V.

Company

Zuidersluisweg 2, 8243RC Lelystad, Switzerland

Similar opportunities